BioCryst Pharmaceuticals | BCRX - 贸易债权人



金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 1.89B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


贸易债权人 更改 日
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
BioCryst Pharmaceuticals USD 15.83M 10.26M 2025-12
Chugai Pharma JPY 107.52B 19.72B 2026-03
Daiichi Sankyo JPY 568.5B 16.84B 2025-12
DBV Technologies USD 39.82M 972K 2025-09
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Gilead Sciences USD 715M 93M 2025-12
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Incyte USD 228.62M 1.41B 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Karyopharm Therapeutics USD 4M 1.39M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Novavax USD 24.58M 9.35M 2025-12
PTC Therapeutics USD 45.49M 8.87M 2025-12
Regeneron Pharmaceuticals USD 1.03B 4.81B 2026-03
Roche Holding CHF 5.78B 1.27B 2025-12
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Ultragenyx Pharmaceutical USD 31M 9.57M 2025-12
Vertex Pharmaceuticals USD 3.47B 40.6M 2026-03